Trishula Therapeutics, Inc.
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2020-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.trishulatx.com
Clinical Trials
4
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC Patients
- Conditions
- Pancreatic Cancer
- First Posted Date
- 2023-11-07
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Trishula Therapeutics, Inc.
- Target Recruit Count
- 194
- Registration Number
- NCT06119217
- Locations
- 🇨🇳
Investigative Site, Taoyuan, Taiwan
🇺🇸Investigative SIte, Hot Springs, Arkansas, United States
TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers
- Conditions
- Solid Tumor, Adult
- First Posted Date
- 2020-03-13
- Last Posted Date
- 2024-04-08
- Lead Sponsor
- Trishula Therapeutics, Inc.
- Target Recruit Count
- 185
- Registration Number
- NCT04306900
- Locations
- 🇺🇸
HonorHealth Research Institute, Scottsdale, Arizona, United States
🇺🇸City of Hope Medical Center Clinical Trials Office, Duarte, California, United States
🇺🇸University of Southern California, Los Angeles, California, United States
TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers
- Conditions
- LymphomaSolid Tumor
- Interventions
- First Posted Date
- 2019-03-21
- Last Posted Date
- 2025-07-02
- Lead Sponsor
- Trishula Therapeutics, Inc.
- Target Recruit Count
- 56
- Registration Number
- NCT03884556
- Locations
- 🇺🇸
UC Irvine Cancer Center, Orange, California, United States
🇺🇸UC Davis Comprehensive Cancer Center, Sacramento, California, United States
🇺🇸University of California, San Francisco, San Francisco, California, United States